Unraveling the role of glutamine metabolism in cancer: from cell death mechanisms to tumor microenvironment modulation.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms and preclinical drug targets without systematic meta-analytic data.
PubMed 42642776 · doi:10.1186/s40164-026-00812-1
What was done
The authors reviewed the biological functions of glutamine metabolism in oncology. They synthesized literature regarding tumor metabolic reprogramming, interactions between glutamine metabolism and regulated cell death pathways under metabolic stress, impacts on the tumor immune microenvironment, and pharmacological agents designed to target glutamine metabolic pathways.
What was found
The abstract provides no quantitative data or specific numerical endpoints. It summarizes qualitative biological concepts, noting that tumor cells demonstrate glutamine addiction through metabolic reprogramming, which influences both their survival adaptability and their susceptibility to regulated cell death. The review also maps these metabolic interactions to immune microenvironment modulation and catalogs current antitumor drugs targeting glutamine metabolism.
Why it matters
Targeting glutamine metabolic dependencies represents an active area of investigation for inducing regulated cell death in tumors and reprogramming the immune microenvironment.
Limits
The abstract describes a broad narrative overview without reporting quantitative effect sizes, systematic search methodology, meta-analytic pooling, or clinical trial outcomes. Details on specific drug efficacy or human safety profiles are not provided in the abstract.
Cited by
- supports Glutamine is the most abundant amino acid in the human bloodstream.